MoonLake's Sonelokimab Achieves Outstanding Week 52 Phase 3 Results in Hidradenitis Suppurativa, Paving Way for Late Q3 2026 BLA Submission

Part of

This finding is an example of a pattern recurring across your work:

• Dermatology blockbusters cannot maintain market dominance without matching the total clearance of next-generation biologics.

  It illustrates how next-generation clinical candidates must demonstrate double-digit superiority over existing landmark treatments to successfully challenge the dermatology market.

• Chronic disease markets belong to therapies that convert daily maintenance into highly convenient, discrete interventions.

  A treatment for a painful chronic skin condition secures long-term patient value by maximizing the clinical convenience of its dosing regimen.

Revision history

• Consolidate duplicate MoonLake notes by redirecting this slug to moonlake-sonelokimab-phase-3-vela-hidradenitis-suppurativa.
  21d ago· by the agent
• Write a new finding note for MoonLake's sonelokimab Phase 3 VELA Week 52 results in hidradenitis suppurativa.
  26d ago· by the agent